Core Viewpoint - Legend Biotech Corporation (LEGN) shows significant upside potential with a mean price target of $79.86, indicating a 135.2% increase from its current price of $33.96 [1] Price Targets - The average of 19 short-term price targets ranges from a low of $55 to a high of $95, with a standard deviation of $11.93, suggesting a variability in estimates [2] - The lowest estimate indicates a 62% increase, while the most optimistic estimate points to a 179.7% upside [2] Analyst Consensus - Analysts have shown strong agreement in revising earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 15.5%, with three estimates moving higher and no negative revisions [12] Zacks Rank - LEGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13]

Group 1 - Enova International (ENVA) shares have increased by 1.8% over the past four weeks, closing at $97.88, with a mean price target of $127.71 indicating a potential upside of 30.5% [1] - The average price target from analysts ranges from a low of $109 to a high of $138, with a standard deviation of $10.80, suggesting a relatively high agreement among analysts regarding the stock's potential movement [2][9] - Analysts show strong agreement in revising earnings estimates higher for ENVA, which correlates with potential stock price increases, as indicated by a 0.3% increase in the Zacks Consensus Estimate for the current year [4][11][12] Group 2 - The Zacks Rank for ENVA is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] - While price targets are often viewed as misleading, the direction implied by the consensus price target for ENVA appears to be a useful guide for potential price movement [7][10][11]